跳至主要内容
临床试验/NCT04126668
NCT04126668已完成1 期

A Pharmacokinetic Study in Chinese Healthy Male and Female Volunteers to Investigate the Effect of Food on the Pharmacokinetics of CM082 Tablet.

AnewPharma1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2019年12月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
24
试验地点
1
主要终点
Peak plasma concentration (Cmax) of CM082

研究概览

简要总结

The main objective of this study is to evaluate the Effect of Food on the Pharmacokinetics of CM082 tablet.

详细描述

The main objective of this study is to evaluate the Effect of Food on the Pharmacokinetics of CM082 tablet in Chinese Healthy Volunteers. In addition, the safety of CM082 tablet in Chinese Healthy Volunteers who with High-fat meal or fasting state will also be evaluated.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • age: 18 - 45 years;
  • sex: male and female;
  • body weight: Male ≥ 50 kg,female ≥ 45 kg, body mass index BMI (weight (kg)/height 2 (m2)) between 19-26 kg/m2 (including border);
  • Healthy as judged by the investigator/subinvestigator based on the results of physical examinations and all lab tests;
  • Abstinence or physical contraception approved by researchers must be approved during and within three months after the trial is completed; and no sperm and egg donation plan is available;
  • Written informed consent;

排除标准

  • Received any investigational drugs within 14 days before the screening test;
  • Donated 200 mL of whole blood within 30 days before the screening test,or donated 200 mL of whole blood during the study or within 30 days after completion of the study;
  • Females who are lactating, pregnant, potentially child-bearing, or willing to get pregnant during the study period;
  • History of drug or food allergies;
  • Abnormal blood pressure or pulse,Abnormal laboratory tests;
  • Participated in other clinical trials within 3 months before screening;
  • Smoking and drinking within 3 months before screening or test results of smoke, alcohol, and drug abuse are positive;
  • Positive for HBsAg, Hepatitis C virus (HCV) antibody, HIV antibody or syphilis antibody;
  • Clinically apparent disease/infection within 1 month before screening;
  • The researchers determined that there were other conditions that were not suitable for the trial;

研究组 & 干预措施

Period 1: fasted control → Period 2: fed control

Experimental

Period 1: administration of CM082 200 mg at 7:30am, without the breakfast;Period 2: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast

干预措施: CM082 with fed or fasting (Drug)

Period 1: fed control → Period 2: fasted control

Experimental

Period 1: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast;Period 2: administration of CM082 200 mg at 7:30am, without the breakfast

干预措施: CM082 with fed or fasting (Drug)

结局指标

主要结局

Peak plasma concentration (Cmax) of CM082

时间窗: pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration)

The effect of food on Cmax after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions

Area under the plasma concentration versus time curve (AUC) of CM082

时间窗: pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration)

The effect of food on AUC after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions

Time of maximum concentration(Tmax)of CM082

时间窗: pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration)

The effect of food on Tmax after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions

Half life(T1/2)of CM082

时间窗: pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration)

The effect of food on T1/2 after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions

次要结局

  • Percentage of adverse events(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 months)

研究者

发起方
AnewPharma
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验